Skip to content

Effect of a Polyphenol-rich Cocoa Extract on Peripheral Blood Mononuclear Cells Gene Expression

Effect of the Administration of a Polyphenol-rich Cocoa Extract on Peripheral Blood Mononuclear Cells Gene Expression in Humans

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01681394
Enrollment
25
Registered
2012-09-07
Start date
2012-06-30
Completion date
2013-02-28
Last updated
2013-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Function, Gene Expression

Brief summary

It has been evidenced that chocolate and cocoa consumption increase vasodilation and reduce blood pressure. However, the mechanisms implicated in these effects have not been elucidated yet. The purpose of this study is to evaluate changes in gene expression induced by the administration of a polyphenol-rich cocoa extract in peripheral blood mononuclear cells (PBMC) in humans.

Detailed description

This is a prospective, randomized, controlled, double-blind and cross-over study. The intervention will consist in the administration of 250g of chocolate cream with or without the extract after 12 hours fasting. Blood samples will be taken at point 0, 2, 3 and 6 hours after the administration. At each time point, blood pressure and endothelial function (with a non-invasive method) will be measured.

Interventions

DIETARY_SUPPLEMENTPolyphenol-rich cocoa extract

250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)

DIETARY_SUPPLEMENTChocolate cream

Sponsors

Technological Centre of Nutrition and Health, Spain
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
20 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

1.Healthy males between the ages of 20 and 39 who do not meet any of the

Exclusion criteria

.

Design outcomes

Primary

MeasureTime frame
Gene expression changes in PBMCs (using a microarray)0-6 hours

Secondary

MeasureTime frame
Blood pressure0-2-3-6 hours
Endothelial function (assessed by ischemic reactive hyperemia)0-2-3-6 hours
Plasma levels of procyanidins metabolites0-6 hours

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026